Skip to main content
. Author manuscript; available in PMC: 2011 Oct 15.
Published in final edited form as: Int J Cancer. 2010 Oct 15;127(8):1741–1747. doi: 10.1002/ijc.25489

Figure 2.

Figure 2

Proposed antitumor mechanism of LL-37 in gastric cancer. LL-37 inhibits proteasomal activity via an unknown mechanism, which leads to upregulation of BMP4 and subsequent activation of BMP signaling. LL-37 also downregulates cyclin E2. These changes result in cell cycle arrest at the late G1-phase.